血液透析患者使用维生素K抑制冠状动脉钙化进展(iPACK-HD研究):一项随机、安慰剂对照、多中心、先导试验
这项随机安慰剂对照多中心先导试验纳入86例冠状动脉钙化评分≥30 Agatston单位的血液透析患者,比较每周三次10 mg叶绿醌与安慰剂对12个月冠状动脉钙化进展的影响。主要结局为可行性,招募率4.4例/月、服药依从性96%达到预设标准;叶绿醌组去磷酸化未羧化MGP显著降低86%,但两组冠状动脉钙化绝对或相对进展无差异。
要点
- 叶绿醌组去磷酸化未羧化MGP降低86%,维生素K状态改善。
- 两组冠状动脉钙化绝对或相对进展无差异。
- 招募率4.4例/月、服药依从性96%,达到预设可行性标准。
核心结论
- 叶绿醌治疗改善维生素K状态,完全把握度的随机试验可能可行。
研究设计与样本
- 平行随机安慰剂对照多中心先导试验,纳入86例冠状动脉钙化评分≥30 Agatston单位的血液透析患者。
- 干预为每周三次10 mg叶绿醌或匹配安慰剂,疗程12个月。
- 主要结局为可行性(招募率、服药依从性、研究完成率和总体方案依从性),冠状动脉钙化评分用于评估基线和12个月钙化。
主要发现
- 69例(80%)完成试验。
- 招募率4.4例/月、服药依从性96%,达到预设可行性标准≥4.17和≥90%。
- 叶绿醌组12个月去磷酸化未羧化MGP降低86%,叶绿醌水平和Gla-骨钙素与Glu-骨钙素比值较安慰剂组升高。
- 两组冠状动脉钙化绝对或相对进展无差异。
关键数值与推荐
- 可行性预设标准:招募率≥4.17例/月,服药依从性≥90%。
- 实际招募率4.4例/月,服药依从性96%。
- 叶绿醌组去磷酸化未羧化MGP降低86%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vitamin K activates matrix Gla protein (MGP), a key inhibitor of vascular calcification. There is a high prevalence of sub-clinical vitamin K deficiency in patients with end-stage kidney disease. METHODS: A parallel randomized placebo-controlled pilot trial was designed to determine whether 10 mg of phylloquinone thrice weekly versus placebo modifies coronary artery calcification progression over 12 months in patients requiring hemodialysis with a coronary artery calcium score (CAC) ≥30 Agatston Units (ClinicalTrials.gov identifier NCT01528800). The primary outcome was feasibility (recruitment rate, compliance with study medication, study completion and adherence overall to study protocol). CAC score was used to assess calcification at baseline and 12 months. Secondary objectives were to explore the impact of phylloquinone on vitamin K-related biomarkers (phylloquinone, dephospho-uncarboxylated MGP and the Gla-osteocalcin to Glu-osteocalcin ratio) and events of clinical interest. RESULTS: A total of 86 patients with a CAC score ≥30 Agatston Units were randomized to either 10 mg of phylloquinone or a matching placebo three times per week. In all, 69 participants (80%) completed the trial. Recruitment rate (4.4 participants/month) and medication compliance (96%) met pre-defined feasibility criteria of ≥4.17 and ≥90%, respectively. Patients randomized to phylloquinone for 12 months had significantly reduced levels of dephospho-uncarboxylated MGP (86% reduction) and increased levels of phylloquinone and Gla-osteocalcin to Glu-osteocalcin ratio compared with placebo. There was no difference in the absolute or relative progression of coronary artery calcification between groups. CONCLUSION: We demonstrated that phylloquinone treatment improves vitamin K status and that a fully powered randomized trial may be feasible.
引用
- Holden RM, Booth SL, Zimmerman D, et al. Inhibit progression of coronary artery calcification with vitamin K in hemodialysis patients (the iPACK-HD study): a randomized, placebo-controlled multi-center, pilot trial. Nephrol Dial Transplant. 2023. PMID: 35641194. doi:10.1093/ndt/gfac191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。